logo-loader
RNS
view4D pharma plc

Director/PDMR Shareholding

/**/ sup{font-size:80%}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue }visited{ color: #954F72 } .be{size:612.0pt 792.0pt;margin:72.0pt 72.0pt 72.0pt 72.0pt;}div.be{}p.dx{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 11.75pt; margin-bottom: 11.0pt; text-align: center}span.dv{font-size:9.0pt;font-family:"Arial","sans-serif"; color:black}p.dy{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: center}span.dt{font-size:10.0pt;line-height:107%;font-family:"Arial","sans-serif"}p.dz{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align: center}p.ea{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.0pt; margin-left: 0cm; margin-right: 0cm; margin-top: 6.0pt; text-align: center}span.dq{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.eb{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;text-align:justify;line-height: 12.65pt} span.do{font-size:10.0pt;font-family:"Arial","sans-serif"}table.ec{margin-left:-5.4pt;border-collapse:collapse}td.dk{width:130.7pt;padding:0cm 5.4pt 0cm 5.4pt}p.ed{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 11.0pt; text-align: justify}span.dm{font-size:10.0pt;font-family:"Arial","sans-serif"; color:black}td.dj{width:3.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.dh{width:67.1pt;padding:0cm 5.4pt 0cm 5.4pt}p.ee{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 11.0pt; text-align: right}td.dg{width:67.15pt;padding:0cm 5.4pt 0cm 5.4pt}p.ef{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: 12.65pt; margin-bottom: 11.0pt; text-align: right} p.eg{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: 12.65pt; margin-bottom: 13.2pt; text-align: justify}p.eh{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:13.2pt;text-align:justify;line-height: 12.65pt}span.dc{font-size:12.0pt;font-family:"Times New Roman","serif"; color:black}table.ei{width:467.5pt;margin-left:-5.4pt;border-collapse:collapse}td.cy{border:solid windowtext 1.0pt;padding:0cm 5.4pt 0cm 5.4pt}p.ej{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 12.1pt}span.da{font-size:10.0pt;font-family:"Arial","sans-serif";color:black; border:none windowtext 1.0pt;padding:0cm}td.cx{width:425.15pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cv{border:solid windowtext 1.0pt;border-top:none; padding:0cm 5.4pt 0cm 5.4pt}p.ek{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:normal} td.cu{width:146.15pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.ct{width:268.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cs{width:425.15pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}p.el{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:13.2pt;line-height:normal}p.em{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:12.1pt;line-height:11.75pt}p.g,li.g,div.g{margin:0cm;margin-bottom:.0001pt;font-size:11.0pt;font-family:"Calibri","sans-serif";}tr.cm{height:23.25pt}td.cp{border:solid windowtext 1.0pt;border-top:none; padding:0cm 5.4pt 0cm 5.4pt;height:23.25pt}td.co{width:146.15pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:23.25pt}td.cn{width:268.2pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:23.25pt} table.en{width:176.25pt;border-collapse:collapse}tr.ci{height:27.25pt}td.ck{width:53.3pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}span.cl{font-size:10.0pt;font-family:"Arial","sans-serif";border:none windowtext 1.0pt; padding:0cm}td.cj{width:58.15pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.ch{width:53.3pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}td.cg{width:58.15pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:27.25pt}p.eo{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal}p.ep{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-div: italic; line-height: normal; margin-bottom: 11.0pt}p.eq{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:11.0pt;line-height:normal} span.ca{color:black}td.bz{width:436.7pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.by{border:none;padding:0cm 0cm 0cm 0cm}p.a,li.a,div.a{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";}td.bx{width:246.25pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bw{width:436.7pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.bv{width:246.25pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt;height:23.25pt}td.bt{width:210.2pt;padding:0cm 0cm 0cm 0cm}p.er{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm}td.br{width:196.3pt;padding:0cm 0cm 0cm 0cm} p.es{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-align: center; text-autospace: ideograph-numeric}p.et{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; text-autospace: ideograph-numeric}td.bo{width:257.3pt;padding:0cm 0cm 0cm 0cm}p.eu{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";line-height: normal; margin-bottom: 0cm; text-align: right; text-autospace: ideograph-numeric}td.bn{border:none}p.ev{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; page-break-after: avoid}table.ew{width:468.0pt}tr.bh{page-break-inside:avoid}td.bj{padding:0cm 0cm 0cm 0cm}p.ex{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; line-height: normal; margin-bottom: 0cm; page-break-after: avoid} span.bl{font-size:10.0pt;font-family: "Arial","sans-serif";color:black}p.ey{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-bottom:0cm;margin-bottom:.0001pt;line-height: normal;}p.ez{margin-top:0cm;margin-right:0cm;margin-bottom:8.0pt;margin-left:0cm;line-height:107%;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold} /**/
RNS Number : 7664Z
4d Pharma PLC
22 May 2019
 

 The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via the Regulatory Information Service, this inside information is now considered to be in the public domain.

4D pharma plc

(the "Company" or "4D")

PDMR Dealings

4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, is pleased to announce that David Norwood, Duncan Peyton and Alex Stevenson (the "Directors") have purchased ordinary shares in the Company as listed below. Following this transaction, the Directors have a resulting interest in the ordinary shares of the Company as listed below.

Name


Shares in 4D pharma plc before purchase

% of total shares in issue

Shares in 4D pharma plc after purchase

% of total shares in issue







David Norwood (Chairman)


7,103,725

10.85%

7,108,725

10.85%

Duncan Peyton (CEO)


 6,343,985

9.69%

 6,445,184

9.84%

Alex Stevenson (CSO)


6,362,138

9.71%

6,413,136

9.79%

 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

 

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

David Norwood

2

Reason for the notification

a)

Position/status

PDMR

b)

 

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

4D Pharma plc

b)

LEI

213800O49VYSXWE2ZD52

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

b)

Nature of the transaction

Purchase of Ordinary Shares

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

96p

5,000

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

e)

Date of the transaction

21st May 2019

f)

Place of the transaction

London Stock Exchange, AIM

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Duncan Peyton

 

2

Reason for the notification

 

a)

Position/status

PDMR

 

b)

 

Initial notification /Amendment

Initial notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

4D Pharma plc

 

b)

LEI

213800O49VYSXWE2ZD52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

 

b)

Nature of the transaction

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

99.4p

101,199

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

 

e)

Date of the transaction

21st May 2019

 

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Alex Stevenson

 

2

Reason for the notification

 

a)

Position/status

PDMR

 

b)

 

Initial notification /Amendment

Initial notification

 

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

Name

4D Pharma plc

 

b)

LEI

213800O49VYSXWE2ZD52

 

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Identification code

Ordinary shares of £0.0025

 

ISIN: GB00BJL5BR07

 

b)

Nature of the transaction

Purchase of Ordinary Shares

 

c)

Price(s) and volume(s)

 Price(s)

Volume(s)

98p

50,998

 

d)

Aggregated information

- Aggregated volume

- Price

 

N/A

 

 

e)

Date of the transaction

21st May 2019

 

f)

Place of the transaction

London Stock Exchange, AIM

 

 

 

 

For further information please contact:

4D


Duncan Peyton, Chief Executive Officer

Fay Weston, Head of Investor Relations

 

 

+ 44 (0)113 895 0130

+ 44 (0)7990 381713

Zeus Capital Limited - Nomad and Joint Broker

+44 (0)161 831 1512

Dan Bate / Jordan Warburton

 


Bryan Garnier & Co. Limited - Joint Broker

+44 (0)20 7332 2500

Dominic Wilson

Phil Walker


 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
DSHEAXSFAAFNEFF

Quick facts: 4D pharma plc

Price: 110

Market: AIM
Market Cap: £72.04 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE